Agnoli Claudia, Perlino Federico, Guerra Giulia, Quartiroli Martina, Vener Claudia, Mauri Pierluigi, de Palma Antonella, Venturelli Elisabetta, Sieri Sabina
Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Biostatistics for clinical research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Int J Biol Markers. 2025 Mar;40(1):75-79. doi: 10.1177/03936155241309927. Epub 2025 Jan 20.
IntroductionBreast cancer is the most common cancer among women, and metabolic syndrome (MetS) is a risk factor for breast cancer, especially postmenopausal breast cancer. We evaluated the role of the advanced glycated end products (AGEs) levels contributing to the association between MetS and breast cancer risk.MethodsPlasma AGEs were measured in a case-control study nested within the Hormones and Diet in the Etiology of Breast Tumors (ORDET) cohort, including 40 incident postmenopausal breast cancer cases (20 with MetS and 20 without) and 40 postmenopausal controls (20 with MetS and 20 without). The association between AGEs and breast cancer was analyzed using Bayesian logistic regression models. An informative prior for the exposure coefficient, modeled as a normal distribution, centered on the natural logarithm of an odds ratio ((OR)=1.635) derived from prior evidence, was employed alongside weakly informative priors (WIPs). Bayesian linear regression with WIPs was used to examine the association between MetS and AGEs. Estimates were reported with SDs and 90% and 95% credible intervals (CI).ResultsAGEs were associated with higher breast cancer risk both with the informative prior (OR = 1.745, SD):0.362; 90% CI:1.218-2.390; 95% CI:1.137-2.548) and the WIP (OR = 1.861, SD = 0.661; 90% CI:1.026-3.082; 95% CI:0.924-3.528) specification. Although the difference in plasma AGEs in women with and without MetS was not significant, we found a suggestion of higher levels in women with MetS (mean difference in standardized AGEs between individuals with and without MetS = 0.155, SD = 0.245; 90% CI:-0.246 to 0.553; 95% CI:-0.322 to 0.625).ConclusionsThese data, although from a small sample of women, support a role of endogenous AGEs in the pathological pathways underlying the association between MetS and breast cancer development.
引言
乳腺癌是女性中最常见的癌症，而代谢综合征（MetS）是乳腺癌的一个风险因素，尤其是绝经后乳腺癌。我们评估了晚期糖基化终产物（AGEs）水平在MetS与乳腺癌风险关联中的作用。
方法
在“乳腺肿瘤病因中的激素与饮食”（ORDET）队列中的一项病例对照研究中测量血浆AGEs，该研究包括40例绝经后乳腺癌新发病例（20例伴有MetS，另20例不伴有MetS）和40例绝经后对照（20例伴有MetS，另20例不伴有MetS）。使用贝叶斯逻辑回归模型分析AGEs与乳腺癌之间的关联。对暴露系数采用信息性先验，建模为正态分布，以先前证据得出的优势比（(OR)=1.635）的自然对数为中心，并与弱信息性先验（WIPs）一起使用。使用带有WIPs的贝叶斯线性回归来检验MetS与AGEs之间的关联。报告的估计值带有标准差以及90%和95%可信区间（CI）。
结果
在使用信息性先验（OR = 1.745，标准差：0.362；90% CI：1.218 - 2.390；95% CI：1.137 - 2.548）和WIP（OR = 1.861，标准差 =
0.661；90% CI：1.026 - 3.082；95% CI：0.924 - 3.528）设定时，AGEs均与较高的乳腺癌风险相关。尽管伴有和不伴有MetS的女性血浆AGEs差异不显著，但我们发现有迹象表明伴有MetS的女性AGEs水平更高（伴有和不伴有MetS的个体标准化AGEs的平均差异 = 0.155，标准差 = 0.245；90% CI：-0.246至0.553；95% CI：-0.322至0.625）。
结论
这些数据虽然来自一小部分女性样本，但支持内源性AGEs在MetS与乳腺癌发展关联的病理途径中发挥作用。
